Press release content from PR Newswire. The AP news staff was not involved in its creation.
Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March
February 11, 2021 GMT
(PRNewsfoto/Aruvant Sciences)
NEW YORK and BASEL, Switzerland, Feb. 11, 2021 /PRNewswire/ Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced management participation in multiple investor and scientific conferences in February and March. The company will be at the following conferences:
BIO CEO & Investor Digital Conference. Will Chou, M.D., Aruvant chief executive officer, will provide an overview of Aruvant and review data examining the company’s lead product candidate ARU-1801 as a potentially curative gene therapy for sickle cell disease. Visit https://www.bio.org/events/bio-ceo-investor-digital-conference/sessions/770479 to view the on-demand p